Stonepine Capital Management »

Candel Therapeutics shares owned by Stonepine Capital Management

Quarter-by-quarter ownership of Candel Therapeutics (CADL) shares owned by Stonepine Capital Management from 13F filings

Historical chart of Stonepine Capital Management investment in Candel Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Candel Therapeutics held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Candel Therapeutics by Stonepine Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $502k 103k 4.90

More positions owned by Stonepine Capital Management

Spdr Series Trust State Street Spd Put Option (XBI)
Verastem Com New (VSTM)
Adma Biologics (ADMA)
Tenax Therapeutics Com New (TENX)
Evolus (EOLS)
Camp4 Therapeutics Corp (CAMP)
Nektar Therapeutics Com New (NKTR)
Terns Pharmaceuticals Call Option (TERN)
Zevra Therapeutics Com New (ZVRA)
Abeona Therapeutics Com New (ABEO)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Establishment Labs Holdings Ord Call Option (ESTA)
Kazia Therapeutics Sponsored Ads (KZIA)
An2 Therapeutics (ANTX)
Alexandria Real Estate Equities Call Option (ARE)

View all positions for Stonepine Capital Management

Top funds holding Candel Therapeutics

FMR
Rtw Investments
Acorn Capital Advisors
BlackRock
Saturn V Capital Management
Portolan Capital Management
Vanguard Capital Management
Vestal Point Capital
Millennium Management
Geode Capital Management
Halter Ferguson Financial
State Street Corporation
Heights Capital Management
Susquehanna International
Sands Capital Ventures

View all funds holding Candel Therapeutics